Heartflow
HTFL
49.36
-1.33
-2.62%
Heartflow
US · HTFL
#2217 by market cap
Listed 2025
49.36
-1.33
-2.62%
Live - 5344 symbols - heartbeat 97s ago
· 2026-10-08 07:28
Pre-market
49.39
+0.06%
After-hours
49.36
0.00%
- Market cap
- 4.29B
- P/E (TTM)i
- -36.16
- P/Bi
- 15.34
- EPSi
- -1.37
- Div yieldi
- 0.00%
- 52W posi
- 85%
Reader sentiment
Are you bullish or bearish on HTFL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 40.05, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 3 years
Latest year +39.92% YoY
Margins
- Gross margin
- 76.80%
- Operating margin
- -36.39%
- Net margin
- -66.35%
Key ratios & quality
- Altman Z-Scorei
- 40.05
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 87.17M | 125.81M | 176.03M |
| Gross profit | 58.05M | 94.45M | 135.20M |
| Selling & admin expenses | 95.11M | 112.15M | 134.35M |
| Research & development | 35.85M | 43.52M | 64.92M |
| Operating profit | -72.91M | -61.22M | -64.07M |
| Pretax profit | -95.11M | -96.37M | -116.87M |
| Tax | 547.00K | 53.00K | -76.00K |
| Net profit | -95.66M | -96.43M | -116.79M |
| Basic EPS | -2 | -1 | -3 |
| Diluted EPS | -1.94 | -1.20 | -3.17 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 37.21M | 43.42M | 46.28M | 49.13M | 52.59M | 64.08M |
| Gross profit | 27.94M | 32.78M | 35.42M | 39.06M | 42.16M | 53.19M |
| Selling & admin expenses | 31.52M | 31.46M | 33.22M | 38.15M | 42.57M | 44.83M |
| Research & development | 13.92M | 15.03M | 17.30M | 18.67M | 21.62M | 26.26M |
| Operating profit | -17.50M | -13.72M | -15.10M | -17.75M | -22.02M | -17.90M |
| Pretax profit | -32.35M | -9.14M | -50.83M | -24.56M | -27.36M | -15.72M |
| Tax | 0 | 59.00K | 30.00K | -165.00K | 23.00K | 22.00K |
| Net profit | -32.35M | -9.20M | -50.86M | -24.40M | -27.38M | -15.74M |
| Basic EPS | 0 | 0 | -1 | 0 | 0 | 0 |
| Diluted EPS | -0.40 | -0.11 | -1.04 | -0.29 | -0.32 | -0.18 |
Balance sheet
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total current assets | 148.45M | 82.29M | 220.20M |
| Cash & ST investments | 122.77M | 51.37M | 176.79M |
| Inventory | -- | -- | -- |
| Total assets | 185.05M | 118.70M | 359.45M |
| Total current liabilities | 32.82M | 33.61M | 42.37M |
| Short-term debt | 5.14M | 5.42M | 5.92M |
| Long-term debt | 134.01M | 136.43M | -- |
| Total liabilities | 962,615,000.00 | 978,188,000.00 | 58,805,000.00 |
| Total equity | -777.56M | -859.48M | 300.65M |
| Retained earnings | -874.53M | -970.96M | -1.09B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 144.64M | 118.44M | 327.79M | 220.20M | 211.83M | 223.97M |
| Cash & ST investments | 109.79M | 80.21M | 291.17M | 176.79M | 158.32M | 162.55M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 184.44M | 159.36M | 364.40M | 359.45M | 344.03M | 344.46M |
| Total current liabilities | 43.41M | 32.94M | 37.85M | 42.37M | 38.02M | 44.09M |
| Short-term debt | 5.45M | 5.49M | 5.52M | 5.92M | 6.38M | 6.78M |
| Long-term debt | 179.66M | 182.42M | -- | -- | -- | -- |
| Total liabilities | 1,073,436,000.00 | 1,054,158,000.00 | 109,830,000.00 | 58,805,000.00 | 58,307,000.00 | 64,736,000.00 |
| Total equity | -889.00M | -894.80M | 254.57M | 300.65M | 285.72M | 279.73M |
| Retained earnings | -1.00B | -1.01B | -1.06B | -1.09B | -1.12B | -1.13B |
Cash flow
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -76.43M | -69.00M | -54.02M |
| Depreciation & amortization | 7.63M | 8.09M | 8.57M |
| Free cash flow | -82.54M | -73.36M | -59.05M |
| Dividends paid | -- | -- | -- |
| Stock buybacks / issuance | -228.00K | 0 | 332.39M |
| Ending cash balance | 127.23M | 55.84M | 49.49M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -13.17M | -27.30M | -2.96M | -10.60M | -30.10M | -8.58M |
| Depreciation & amortization | 2.10M | 2.14M | 2.09M | 2.25M | 2.43M | 2.26M |
| Free cash flow | -14.27M | -28.09M | -4.19M | -12.50M | -31.99M | -10.50M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 332.78M | -397.00K | 3.29M | 0 |
| Ending cash balance | 114.26M | 84.69M | 295.64M | 49.49M | 24.37M | 39.06M |
Returns & efficiency
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| ROE %i | -- | -- | -- |
| ROA %i | -66.84 | -63.49 | -48.85 |
| ROIC %i | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- |
| EBIT margin %i | -80.77 | -58.51 | -57.77 |
| FCF / sales %i | -- | -- | -- |
| Current ratioi | 4.52 | 2.45 | 5.20 |
| Quick ratioi | 4.37 | 2.26 | 4.86 |
| Debt / assetsi | 86.79 | 135.11 | 6.14 |
| LT debt / equityi | -- | -- | 5.37 |
| Interest coveragei | -2.85 | -3.23 | -6.70 |
| Revenue CAGR (3Y) %i | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -49.25 | -- | -- | -- |
| ROA %i | -58.47 | -58.77 | -34.41 | -48.85 | -42.32 | -46.99 |
| ROIC %i | -- | -- | -40.56 | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -63.23 | -48.09 | -64.84 | -57.77 | -53.18 | -54.23 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.33 | 3.60 | 8.66 | 5.20 | 5.57 | 5.08 |
| Quick ratioi | 3.18 | 3.34 | 8.43 | 4.86 | 5.10 | 4.66 |
| Debt / assetsi | 110.21 | 128.73 | 5.98 | 6.14 | 7.66 | 7.88 |
| LT debt / equityi | -- | -- | 6.39 | 5.37 | 6.99 | 7.27 |
| Interest coveragei | -3.98 | -3.22 | -5.17 | -6.70 | -10.10 | -33.22 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Non-invasive coronary artery disease (CAD) detection solutions100.00%
Quote time 2026-10-08 07:28:40 · For reference only, not investment advice and not tailored to your situation.